Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Inclusion Criteria

• INCLUSION CRITERIA - Age of at least 18 years at the time of signing the informed consent. - Cytologically or histologically confirmed ES-SCLC (American Joint Committee on Cancer [AJCC] 8th edition) and is untreated or received ≤1 cycle of platinum-etoposide and PD-L1 inhibitor therapy. It is acceptable to omit the first dose of PD-L1 inhibitor therapy due to logistical reasons if receiving SoC during or prior to the start of the screening period. - Subject is a candidate for therapy with SoC which includes: - Carboplatin for a maximum of 4 cycles - Etoposide for a maximum of 4 cycles - Atezolizumab - At least 1SSTR-PET imaging-positive measurable site of disease (according to RECIST v1.1) and ≥50% of RECIST v1.1 measurable metastatic lesions must be SSTR-imaging positive. - Adequate hematologic, renal and hepatic function EXCLUSION CRITERIA - Prior exposure to immune-mediated therapy, - Known active or suspected autoimmune disease or any condition requiring systemic treatment with immunosuppressive medications within 14 days prior to first dose of study drug - History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis. Note: History of radiation pneumonitis is permitted. - Severe infection within 4 weeks and/or treatment with therapeutic oral or i.v. antibiotics within 2 weeks prior to initiation of study treatment. - Prior allogeneic stem cell or solid organ transplantation. - Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab. - Radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy. Radiation therapy outside of the chest for palliative care is allowed but must be completed >2 weeks prior to first dose of study drug. - Significant cardiovascular disease and/or resistant hypertension - Subjects with previously treated central nervous system (CNS) metastases who have not recovered from acute side effects of radiotherapy.